echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > NEJM: Upadacitinib is better than adalimumab in treating psoriatic arthritis

    NEJM: Upadacitinib is better than adalimumab in treating psoriatic arthritis

    • Last Update: 2021-04-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The oral Janus kinase inhibitor Upadacitinib has been approved to treat rheumatoid arthritis.


    Researchers recently launched the SELECT-PsA 1 study to evaluate the efficacy and safety of Upadacitinib treatment in patients with psoriatic arthritis who have not responded to or are intolerant to traditional antirheumatic drug treatments .


    Researchers have recently launched the SELECT-PsA 1 study to evaluate the efficacy and safety of Upadacitinib treatment in patients with psoriatic arthritis who have not responded to or are intolerant to traditional antirheumatic drug treatments.


    In this 24-week phase III trial, patients were randomized to receive oral Upadacitinib (15 mg or 30 mg once daily), placebo, or subcutaneous adalimumab (40 mg every 2 weeks).


    1704 patients participated in the study.


    At week 12, the proportion of patients who responded to ACR20 in each group was as follows: 70.


    Differences in ACR20 response rates between groups

    Studies believe that for patients with psoriatic arthritis, Upadacitinib treatment is better than placebo in terms of ACR20 response at week 12, and the 30mg Upadacitinib treatment group is better than adalimumab .


    For patients with psoriatic arthritis, Upadacitinib treatment was better than placebo in terms of ACR20 response at week 12.


    Original source:

    Iain B.


    Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.